Trial Profile
Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no standard therapy exists
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Liposarcoma
- Focus Therapeutic Use
- 04 Jun 2019 Results (n=39) assessing tumor and plasma biomarkers that are differently expressed in long responders (LRs) PFS > 24 w, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.
- 22 Mar 2018 The study has been completed in Spain (End date: 2018-03-02)